Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06340230
Status:
RECRUITING
Last Update Posted:
2024-04-01
First Post:
2024-03-25
Brief Title:
SHR-A1811 Alone or in Combination With Adebrelimab as Neoadjuvant Treatment in ER PositiveHER2 Low Breast Cancer
Sponsor:
Shengjing Hospital
Organization:
Shengjing Hospital
Organization Data
Organization:
Shengjing Hospital
Class:
OTHER
Study ID:
BC-NEO-IIT-SHR-A1811-SHR1316
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Shengjing Hospital
Lead Sponsor Class:
OTHER
Responsible Party:
Caigang Liu
Responsible Party Title:
Director of the Cancer Center
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Shengjing Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Jiangsu HengRui Medicine Co Ltd | INDUSTRY |